The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent

Obesity Reviews

Volumn 2, Issue 3, 2001, Pages 199-211

  Greenway, F L ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Caffeine; Ephedrine; Obesity

Indexed keywords

AMINOPHYLLINE; CAFFEINE; EPHEDRINE; PLANT MEDICINAL PRODUCT; THEOPHYLLINE;

ANIMAL; HUMAN; OBESITY; REVIEW; WEIGHT REDUCTION;

AMINOPHYLLINE; ANIMALS; CAFFEINE; EPHEDRINE; HUMANS; OBESITY; PLANT PREPARATIONS; THEOPHYLLINE; WEIGHT LOSS;

EID: 0035427921     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789x.2001.00038.x     Document Type: Article

References (109)

1. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833-1838.
2. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 1999; 58: 807-810.
3. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Juhl E, Quaade F. Ephedrine as an anorectic: the story of the 'Elsinore pill'. Int J Obes 1981; 5: 183-187.
4. th ed. Macmillan Publishing Company: New York, 1985.
5. Miller DS. A controlled trial using ephedrine in the treatment of obesity [letter]. Int J Obes 1986; 10: 159-160.
6. Cardinale, V (ed.). Drug Topics Red Book. Medical Economics Company, Inc: Montvale, 2000.
7. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995; 19: S2-S7.
8. Chen MD, Lin WH, Song YM, Lin PY, Ho LT. Effect of caffeine on the levels of brain serotonin and catecholamine in the genetically obese mice. Chung Hua I Hsueh Tsa Chih (Taipei) 1994; 53: 257-261.
9. Oberman Z, Herzberg M, Jaskolka H, Harell A, Hoerer E, Laurian L. Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. Isr J Med Sci 1975; 11: 33-36.
10. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 1980; 33: 989-997.
11. Jung RT, Shetty PS, James WP, Barrand MA, Callingham BA. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. Clin Sci 1981; 60: 527-535.
12. Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr 1989; 49: 44-50.
13. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995; 269: E671-E678.
14. Bondi M, Grugni G, Velardo A et al. Adrenomedullary response to caffeine in prepubertal and pubertal obese subjects. Int J Obes Relat Metab Disord 1999; 23: 992-996.
15. Tagliabue A, Terracina D, Cena H, Turconi G, Lanzola E, Montomoli C. Coffee induced thermogenesis and skin temperature. Int J Obes Relat Metab Disord 1994; 18: 537-541.
16. Yoshida T, Sakane N, Umekawa T, Kondo M. Relationship between basal metabolic rate, thermogenic response to caffeine, and body weight loss following combined low calorie and exercise treatment in obese women. Int J Obes Relat Metab Disord 1994; 18: 345-350.
17. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol 1985; 20: 61-66.
18. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25: 103-114.
19. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord 1995; 19: 234-239.
20. Haffner SM, Knapp JA, Stern MP, Hazuda HP, Rosenthal M, Franco LJ. Coffee consumption, diet, and lipids. Am J Epidemiol 1985; 122: 1-12.
21. La Vecchia C, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987; 125: 832-843.
22. Toner JM, Close CF, Ramsay LE. Factors related to treatment resistance in hypertension. Q J Med 1990; 77: 1195-1204.
23. Ohayon MM, Guilleminault C, Priest RG, Caulet M. Snoring and breathing pauses during sleep: telephone interview survey of a United Kingdom population sample. BMJ 1997; 314: 860-863.
24. Gartside PS, Glueck CJ. Relationship of dietary intake to hospital admission for coronary heart and vascular disease: the NHANES II national probability study. J Am Coll Nutr 1993; 12: 676-684.
25. Stamler J, Caggiula A, Grandits GA, Kjelsberg M, Cutler JA. Relationship to blood pressure of combinations of dietary macronutrients. Findings of the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1996; 94: 2417-2423.
26. Wakabayashi K, Kono S, Shinchi K, Honjo S, Todoroki I, Sakurai Y, Umeda T, Imanishi K, Yoshizawa N. Habitual coffee consumption and blood pressure: a study of self-defense officials in Japan. Eur J Epidemiol 1998; 14: 669-673.
27. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA 1994; 271: 280-283.
28. Noble R. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine. Drug Intell Clin Pharm 1988; 22: 296-299.
29. Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995; 49: 37-50.
30. Ramadan NM. Headache caused by raised intracranial pressure and intracranial hypotension. Curr Opin Neurol 1996; 9: 214-218.
31. Massoudi M, Miller DS. Ephedrine, a thermogenic and potential slimming drug. Proc Nutr Soc 1977; 36: 135A.
32. Yen TT, McKee MM, Bemis KG. Ephedrine reduces weight of viable yellow obese mice (Avy/a). Life Sci 1981; 28: 119-128.
33. Wilson S, Arch JR, Thurlby PL. Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 1984; 35: 1301-1309.
34. Massoudi M, Evans E, Miller DS. Thermogenic drugs for the treatment of obesity: screening using obese rats and mice. Ann Nutr Metab 1983; 27: 26-37.
35. Dulloo AG, Miller DS. Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models. Br J Nutr 1984; 52: 179-196.
36. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord 1995; 19: 678-685.
37. Bukowiecki L, Jahjah L, Follea N. Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. Int J Obes 1982; 6: 343-350.
38. Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. Gen Pharmacol 1986; 17: 243-246.
39. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. Am J Clin Nutr 1987; 45: 564-569.
40. Sapeika N. Drugs in obesity. S Afr Med J 1974; 48: 2027-2030.
41. Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr 1985; 42: 83-94.
42. Astrup A, Madsen J, Holst JJ, Christensen NJ. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. Metabolism 1986; 35: 260-265.
43. Pasquali R, Baraldi G, Cesari MP et al. A controlled trial using ephedrine in the treatment of obesity. Int J Obes 1985; 9: 93-98.
44. Pasquali R, Cesari MP, Besteghi L, Melchionda N, Balestra V. Thermogenic agents in the treatment of human obesity: preliminary results. Int J Obes 1987; 11: 23-26.
45. Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 1987; 11: 163-168.
46. Pasquali R, Casimirri F, Melchionda N, Grossi G, Bortoluzzi L, Morselli Labate AM, Stefanini C, Raitano A. Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci (Colch) 1992; 82: 85-92.
47. Nielsen B, Astrup A, Samuelsen P, Wengholt H, Christensen NJ. Effect of physical training on thermogenic responses to cold and ephedrine in obesity. Int J Obes Relat Metab Disord 1993; 17: 383-390.
48. Astrup A. Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation. Acta Endocrinol Suppl 1986; 278: 1-32.
49. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. Aliment Pharmacol Ther 1991; 5: 413-418.
50. Jaedig S, Henningsen NC. Increased metabolic rate in obese women after ingestion of potassium, magnesium- and phosphate-enriched orange juice or injection of ephedrine. Int J Obes 1991; 15: 429-436.
51. Horton TJ, Geissler CA. Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women. Int J Obes 1991; 15: 359-366.
52. Geissler CA. Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women. Int J Obes Relat Metab Disord 1993; 17: S45-S48.
53. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: S65-S68.
54. Dvorak R, Starling RD, Calles-Escandon J, Sims EA, Poehlman ET. Drug therapy for obesity in the elderly. Drugs Aging 1997; 11: 338-351.
55. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies. Am J Clin Nutr 1986; 43: 388-394.
56. Dulloo AG, Miller DS. Reversal of obesity in the genetically obese fa/fa Zucker rat with an ephedrine/methylxanthines thermogenic mixture. J Nutr 1987; 117: 383-389.
57. Tulp OL, Buck CL. Caffeine and ephedrine stimulated thermogenesis in LA-corpulent rats. Comp Biochem Physiol C 1986; 85: 17-19.
58. Dulloo AG, Miller DS. Prevention of genetic fa/fa obesity with an ephedrine-methylxanthines thermogenic mixture. Am J Physiol 1987; 252: R507-R513.
59. Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Am J Clin Nutr 1998; 68: 42-51.
60. Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman BM, Flier JS. Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. Endocrinology 1990; 126: 1514-1520.
61. Napolitano A, Lowell BB, Flier JS. Alterations in sympathetic nervous system activity do not regulate adipsin gene expression in mice. Int J Obes 1991; 15: 227-235.
62. Spurlock ME, Hahn KJ, Miner JL. Regulation of adipsin and body composition in the monosodium glutamate (MSG)-treated mouse. Physiol Behav 1996; 60: 1217-1221.
63. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 1992; 41: 1233-1241.
64. Malecka-Tendera E. Effect of ephedrine and theophylline on weight loss, resting energy expenditure and lipoprotein lipase activity in obese over-fed rats. Int J Obes Relat Metab Disord 1993; 17: 343-347.
65. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M. Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. Int J Obes Relat Metab Disord 1995; 19: 717-722.
66. Han LK, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999; 23: 98-105.
67. Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord 2000; 24: 252-258.
68. Stokholm KH, Hansen MS. Lowering of serum total T3 during a conventional slimming regime. Int J Obes 1983; 7: 195-199.
69. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. Int J Obes 1986; 10: 467-481.
70. Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. Trans Assoc Am Physicians 1990; 103: 307-312.
71. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991; 40: 323-329.
72. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992; 16: 269-277.
73. Toubro S, Astrup A, Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord 1993; 17: S73-S77.
74. Astrup A, Toubro S, Christensen NJ, Quaade F. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992; 55: 246S-248S.
75. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993; 17: S41-S43.
76. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17: S73-S78.
77. Astrup A, Buemann B, Christensen NJ, Toubro S, Thorbek G, Victor OJ, Quaade F. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41: 686-688.
78. Buemann B, Marckmann P, Christensen NJ, Astrup A. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. Int J Obes Relat Metab Disord 1994; 18: 329-332.
79. Molnar D. Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. Int J Obes Relat Metab Disord 1993; 17: S49-S52.
80. Molnar D, Torok K, Erhardt E, Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. [in Process Citation] Int J Obes Relat Metab Disord 2000; 24: 1573-1578.
81. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA. Combined drug treatment of obesity. Obes Res 1995; 3: 497S-500S.
82. Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord 1994; 18: 99-103.
83. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7: 523-531.
84. Waluga M, Janusz M, Karpel E, Hartleb M, Nowak A. Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. Clin Physiol 1998; 18: 69-76.
85. Dulloo AG, Duret C, Rohrer D et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999; 70: 1040-1045.
86. Norregaard J, Jorgensen S, Mikkelsen KL et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharmacol Ther 1996; 60: 679-686.
87. Svendsen TL, Ingerslev J, Mork A. Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity. Ugeskr Laeger 1998; 160: 4073-4075.
88. Altschuler S, Conte A, Sebok M, Marlin RL, Winick C. Three controlled trials of weight loss with phenylpropanolamine. Int J Obes 1982; 6: 549-556.
89. Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 1992; 55: 203S-205S.
90. Jequier E. Energy utilization in human obesity. Ann N Y Acad Sci 1987; 499: 73-83.
91. Drew R. Nonprescription appetite suppressants. N C Med J 1983; 44: 573-574.
92. Zgourides GD, Warren R, Englert ME. Ephedrine-induced thermogenesis as an adjunct to cognitive restructuring and covert conditioning: a proposal for treatment of obese individuals. Percept Mot Skills 1989; 69: 563-572.
93. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements [see comments]. Med J Aust 1999; 171: 604-608.
94. Poston WS, 2nd Foreyt JP, Borrell L, Haddock CK. Challenges in obesity management [see comments]. South Med J 1998; 91: 710-720.
95. Doucet E, Tremblay A. Food intake, energy balance and body weight control. Eur J Clin Nutr 1997; 51: 846-855.
96. Dulloo AG, Stock MJ. Ephedrine in the treatment of obesity [editorial]. Int J Obes Relat Metab Disord 1993; 17: S1-S2.
97. Ryan DH. Medicating the obese patient. Endocrinol Metab Clin North Am 1996; 25: 989-1004.
98. Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996; 52: 696-724.
99. Finer N. Present and future pharmacological approaches. Br Med Bull 1997; 53: 409-432.
100. Carek PJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs 1999; 57: 883-904,
101. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-875.
102. Bray GA. Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 131-148.
103. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998; 106: 29-34.
104. Astrup AV. Treatment of obesity with thermogenic agents [editorial]. Nutrition 1989; 5: 70.
105. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: 'over-the-counter' drugs that interact to stimulate thermogenesis in the obese. Nutrition 1989; 5: 7-9.
106. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993; 17: S35-S40.
107. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995; 3: 537S-540S.
108. Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. Int J Obes Relat Metab Disord 1992; 16: 715.
109. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. BMJ 1997; 314: 29-34.